SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (7290)12/13/1999 1:55:00 AM
From: Vector1  Respond to of 9719
 
Bob,
I agree that IDPH would have had a good year whether or not the BLA filing was accepted. However, if the BLA was accepted CLTR would have had an Advisory committee review this past October and Bex would be approved before the end of the year. In combination with the Fludarabine data I think we would be looking at a IDPH stock price well below $100 per share. CLTR's stock price would be in excess of $50.
v1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News